Skip to content

Income Tax at other companies

Biogen logo
BiogenBIIB
$58.2M-17.7%
Incyte logo
IncyteINCY
$40.27M-47.0%
AbbVie logo
AbbVieABBV
$342M-8.1%
Nuvation Bio logo
Nuvation BioNUVB
$0
Arcus Biosciences logo
Arcus BiosciencesRCUS
$0
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
$1M0.0%

Other financials

Income statement

See full
Revenue$64.9M+224%
Operating income-$34.2M+59.2%
Net income-$42.7M+49.7%
EPS (diluted)-$0.48+51.0%

Balance sheet

See full
Cash & equivalents$130.9M-15.0%
Total debt$350.5M+4.2%
Total equity$41.6M-80.6%
Total assets$472.7M-26.2%

Cash flow

See full
Operating cash flow-$50.3M+47.1%
CapEx$46.8K
Free cash flow-$80.8M-17.6%

Valuation

See full
Market cap$1.74B+95.0%
Enterprise value$1.96B+84.0%
P/S-12.4×

Profitability

See full
Operating margin-102.8%-47.8pp
Net margin-111.9%-51.5pp
FCF margin-187.2%-85.4pp

Returns & leverage

See full
Return on equity-189.5%-8,509pp
Debt / equity8.4×+6.9×
Current ratio5.5×-0.3×

Where this comes from

Reported directly by Syndax Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:IncomeTaxExpenseBenefit.

The official record: Syndax Pharmaceuticals’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Syndax Pharmaceuticals's income tax.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Syndax Pharmaceuticals's income tax?
Syndax Pharmaceuticals (SNDX) reported income tax of $0 in Q1 2026.
What does income tax mean?
Total income tax expense (current + deferred) recognized in the income statement, representing the company's total tax obligation on pre-tax income.